Evidence map›Paper›PMID 37242516›Full record

ReviewPharmaceuticals (Basel, Switzerland)2023

Characterization of Pharmaceutical Tablets by X-ray Tomography.

Jaianth Vijayakumar, Niloofar Moazami Goudarzi, Guy Eeckhaut, Koen Schrijnemakers, Veerle Cnudde, Matthieu N Boone

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jaianth VijayakumarCentre for X-ray Tomography (UGCT), Ghent University, Proeftuinstraat 86/N3, 9000 Gent, Belgium.ORCID 0000-0001-5098-5635
Niloofar Moazami GoudarziCentre for X-ray Tomography (UGCT), Ghent University, Proeftuinstraat 86/N3, 9000 Gent, Belgium.ORCID 0000-0002-1294-6157
Guy EeckhautJanssen Pharmaceutica, Turnhoutseweg 30, 2340 Beerse, Belgium.
Koen SchrijnemakersJanssen Pharmaceutica, Turnhoutseweg 30, 2340 Beerse, Belgium.
Veerle CnuddeCentre for X-ray Tomography (UGCT), Ghent University, Proeftuinstraat 86/N3, 9000 Gent, Belgium.ORCID 0000-0002-3269-5914
Matthieu N BooneCentre for X-ray Tomography (UGCT), Ghent University, Proeftuinstraat 86/N3, 9000 Gent, Belgium.ORCID 0000-0002-5478-4141
Ghent University · BEJanssen (Belgium) · BEUtrecht University · NL

Funding

BOF project BOF24Y2018000702VLAIO-project XToPa HBC.2019.2278
6 · The paper itself

Abstract

Solid dosage forms such as tablets are extensively used in drug administration for their simplicity and large-scale manufacturing capabilities. High-resolution X-ray tomography is one of the most valuable non-destructive techniques to investigate the internal structure of the tablets for drug product development as well as for a cost effective production process. In this work, we review the recent developments in high-resolution X-ray microtomography and its application towards different tablet characterizations. The increased availability of powerful laboratory instrumentation, as well as the advent of high brilliance and coherent 3rd generation synchrotron light sources, combined with advanced data processing techniques, are driving the application of X-ray microtomography forward as an indispensable tool in the pharmaceutical industry.

Indexed as

image processingpharmaceutical tabletsX-ray tomographyX-ray tomography modalities

Identifiers

PMID37242516
PMCPMC10224568
OpenAlexW4376278675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.